Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | EDNRA | P25101 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | EDNRB | P24530 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29666239 | 1.00 | KAT6A (0.45) | KAT6ASLC22A12MCL1ALDH1A1TP53 | |
| SCHEMBL29666106 | 0.89 | ALDH1A1 (0.47) | KAT6AALDH1A1EDNRAACLYLMNA | |
| SCHEMBL22980536 | 0.89 | ALDH1A1 (0.47) | KAT6AALDH1A1EDNRAACLYLMNA | |
| SCHEMBL22980349 | 0.89 | ACLY (0.42) | SLC22A12MCL1ALDH1A1RXFP1L3MBTL1 | |
| SCHEMBL29434836 | 0.89 | ACLY (0.42) | SLC22A12MCL1ALDH1A1RXFP1L3MBTL1 | |
| SCHEMBL29666209 | 0.88 | ALDH1A1 (0.49) | ALDH1A1TDP1EDNRAGRM4LMNA | |
| SCHEMBL22980321 | 0.88 | ALDH1A1 (0.49) | ALDH1A1TDP1EDNRAGRM4LMNA | |
| SCHEMBL23010751 | 0.88 | BRPF1 (0.47) | KAT6AALDH1A1EDNRAACLYGRM4 | |
| SCHEMBL22981705 | 0.85 | SLC22A12 (0.44) | SLC22A12MCL1ALDH1A1EDNRAACLY | |
| SCHEMBL29434842 | 0.85 | SLC22A12 (0.44) | SLC22A12MCL1ALDH1A1EDNRAACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12065399-B2 | Arylsulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-08-20 | — | — | US | claimed |
| EP-4013495-B1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2023-09-27 | — | — | EP | claimed |
| EP-4013495-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-06-22 | — | — | EP | claimed |
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | claimed |
| CN-114174266-A | Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators | 豪夫迈·罗氏有限公司 | 2022-03-11 | — | — | CN | claimed |
| WO-2021028512-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-02-18 | — | — | WO | claimed |
| US-12065399-B2 | Arylsulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-08-20 | — | — | US | disclosed |
| EP-4013495-B1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2023-09-27 | — | — | EP | disclosed |
| EP-4013495-B1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2023-09-27 | — | — | EP | disclosed |
| EP-4013495-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
| CN-114174266-A | Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators | 豪夫迈·罗氏有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021028512-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028512-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | ARSA, SULT1E1, STS | KAT6A 1863/4885SLC22A12 1630/4885MCL1 1086/4885 |
| US-12065399-B2 | Arylsulfonamide derivatives | ARSA, SULT1E1, STS | KAT6A 1863/4885SLC22A12 1630/4885MCL1 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.